Homozygosity at the C677T of the MTHFR gene is associated with increased breast cancer risk in the Turkish population.

BACKGROUND: Folate deficiency is implicated in cancer development. Single nucleotide polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene can modulate the effect of folate. In this case-controlled study, a possible effect of the common MTHFR C677T (ala-->val) polymorphism on breast cancer susceptibility in Turkish patients was investigated. MATERIALS AND METHODS: Polymorphism analysis was performed by melting curve analysis. RESULTS: The variant allele valine (677T) was more frequent among the patients (30.1%) than in controls (23.9%). This difference was weakly significant (p = 0.046; OR = 1.37) and due to a significantly higher frequency of the valine homozygotes (677TT) among the patients (12.1% vs. 5.4%; p = 0.013, OR = 2.5). Among the patients diagnosed at more than 40 years of age, a more pronounced association of the valine homozygotes with breast cancer risk was observed (p = 0.009; OR = 3.3). CONCLUSION: Homozygosity for the low-activity C677T genotype (TT) may represent a genetic determinant increasing breast cancer risk.

BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.

To date, BRCA1 and BRCA2 mutations in breast and/or ovarian patients have not been characterized in the Turkish population. We investigated the presence of BRCA mutations in 53 individuals with a personal and family history of breast and/or ovarian cancer, and 52 individuals with a personal history of breast cancer diagnosed below age 50 without additional family history. We have identified 11 mutations (nine BRCA1 and two BRCA2) using combined techniques involving protein truncation test, direct sequencing and heteroduplex analysis. We found eight out of 53 patients (15.1%) with a family history to carry BRCA gene mutations (seven BRCA1 and one BRCA2). Of these, four were found in 43 families presenting only breast cancer histories, and four were found in families presenting ovarian cancer with or without breast cancer. We also demonstrated two BRCA1 and one BRCA2 mutations in three out of 52 (5.8%) early-onset breast cancer cases without additional family history. Three of nine BRCA1 and both BRCA2 mutations detected in this study were not reported previously. These mutations may be specific to the Turkish population. The BRCA1 5382insC mutation, specific to Ashkenazi and Russian populations, was found twice in our study group, representing a possible founder mutation in the Turkish population.